
Chapter 2: Important information
2-4
Fresenius Medical Care multiFiltrate IFU-EN-UK 15A-2015
2.6.3
Treatment modes and fields of application
SCUF
– Diuretic resistant fluid retention, especially in the event of cardiac
insufficiency or pulmonary oedema.
Pre CVVH, Post CVVH,
Pre-Post CVVH, CVVHD,
Pre CVVHDF, and
Post CVVHDF
– Acute renal insufficiency.
– Removal of toxic metabolic products.
– Treatment of life-threatening electrolyte imbalance,
e.g., hyperkalaemia.
– Correction of the acid-base status, e.g., metabolic acidosis.
– Diuretic resistant fluid retention, especially in the event of cardiac
insufficiency or pulmonary oedema.
Haemoperfusion
– Removal of toxic substances, also protein-bound substances by
adsorption.
Plasma separation
– Removal of plasma, e.g.,
for removing pathological immunoglobulins,
for removing protein-bound toxins or for administering sufficient
quantities of physiological proteins contained in donor plasma.
2.6.4
Anticoagulation of the extracorporeal blood circuit
Most patients need an anticoagulant to prevent their blood from
coagulating in the extracorporeal blood circuit. This can be performed
systemically, i.e., also in the patient's body, or regionally limited to the
extracorporeal blood circuit.
Systemic anticoagulation
The integrated heparin pump can be used for the continuous
anticoagulation of the blood.
Regional anticoagulation
with citrate
The Ci-Ca function integrated in the system permits regional
anticoagulation in the extracorporeal blood circuit with citrate. Citrate
anticoagulation can be used on most patients with CRRT indication.
Exceptions (see chapter 2.6.7 on page 2-6).
This function is intended to be used for adults and can be especially
efficient in the following cases:
– Patients with a bleeding risk, that is, patients on whom systemic
anticoagulation cannot be used at all or only to a degree that is
inadequate for continuous renal replacement therapy.
– Patients with whom the haemofilter rapidly and repeatedly becomes
clogged when different anticoagulation methods are used.
Warning
Any treatment in connection with citrate anticoagulation may only be
performed in intensive care units or under similarly close monitoring.
Содержание multiFiltrate
Страница 1: ...multiFiltrate Instructions for Use Software version 5 3 Edition 15A 2015 Part no M56 963 1 ...
Страница 2: ......
Страница 11: ...Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 xi 15 2 Instructions on the use of free software 15 2 ...
Страница 12: ...xii Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 16: ...Chapter 1 Index 1 4 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 42: ...Chapter 3 Design 3 10 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 166: ...Chapter 4 Operation 4 124 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 Interrupting the treatment ...
Страница 186: ...Chapter 5 Alarm processing 5 20 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 188: ...Chapter 6 Cleaning disinfection 6 2 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 218: ...Chapter 7 Functional description 7 30 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 228: ...Chapter 9 Installation 9 4 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 234: ...Chapter 11 Technical Safety Checks maintenance procedures 11 2 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 252: ...Chapter 12 Specifications 12 18 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 260: ...Chapter 13 Definitions 13 8 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 266: ...Chapter 14 Options 14 6 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...
Страница 282: ...Chapter 15 Appendix 15 16 Fresenius Medical Care multiFiltrate IFU EN UK 15A 2015 ...